The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Encorafenib, cetuximab, and cytotoxic chemotherapy combinations in BRAFV600E CRC murine models.
 
Melanie Nicole Woods
No Relationships to Disclose
 
Vincenzo De Falco
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb; Novartis; Roche/Genentech
 
Claudia Prisco
No Relationships to Disclose
 
Giulia Martini
No Relationships to Disclose
 
Luigi Pio Guerrera
No Relationships to Disclose
 
Valentina Belli
No Relationships to Disclose
 
Teresa Troiani
No Relationships to Disclose
 
Van K. Morris
Honoraria - Projects in Knowledge
Consulting or Advisory Role - Array Biopharma; Axiom Healthcare Strategies; Bicara Therapeutics; BioMedical Insights; Boehringer Ingelheim; Incyte; SERVIER
Research Funding - BioNTech (Inst); Boehringer Ingelheim; Bristol-Myers Squibb (Inst); EMD Serono (Inst); Immatics; Pfizer (Inst)
 
John Paul Y.C. Shen
Stock and Other Ownership Interests - Agios; Syndax; Syndax
 
Hey Min Lee
Stock and Other Ownership Interests - 10x Genomics; Johnson & Johnson; Medtronic
 
Oscar Villarreal
No Relationships to Disclose
 
Alexey Sorokin
No Relationships to Disclose
 
Preeti Kanikarla Marie
No Relationships to Disclose
 
Fortunato Ciardiello
Consulting or Advisory Role - Amgen; Bayer; Merck KGaA; Pfizer; Roche/Genentech
Research Funding - Amgen (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Roche/Genentech (Inst); SERVIER (Inst); Symphogen (Inst)
 
Scott Kopetz
Stock and Other Ownership Interests - Iylon; Lutris; MolecularMatch; Navire
Consulting or Advisory Role - Abbvie; Amal Therapeutics; AstraZeneca/MedImmune; Bayer Health; Bicara Therapeutics; Boehringer Ingelheim; Boston Biomedical; Carina Biotech; Daiichi Sankyo; EMD Serono; EMD Serono; Endeavor BioMedicines; Flame Biosciences; Genentech; Gilead Sciences; GlaxoSmithKline; HalioDx; Holy Stone Healthcare; Inivata; Ipsen; Iylon; Jacobio; Jazz Pharmaceuticals; Lilly; Lutris; Merck; Mirati Therapeutics; Natera; Novartis; Numab; Pfizer; Pierre Fabre; Redx Pharma; Repare Therapeutics; Servier; Xilis
Research Funding - Amgen (Inst); Array BioPharma (Inst); Biocartis (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Guardant Health (Inst); Lilly (Inst); MedImmune (Inst); Novartis (Inst); Sanofi (Inst)
 
Stefania Napolitano
No Relationships to Disclose